Evidence map›Paper›PMID 26409435›Full record

ArticleCancer letters2015

Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.

Mitchell Cheung, Yuwaraj Kadariya, Jacqueline Talarchek, Jianming Pei, Jill A Ohar, Omar R Kayaleh, Joseph R Testa

Abstract read
In one paragraph

Article in Cancer letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. An overview of BAP1 biological functions and current therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Diagnostics ofDiagnostics (Basel, Switzerland) · 2022
    Article
  9. Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Melanoma Risk and Melanocyte Biology.Acta dermato-venereologica · 2020
    Review
  18. Article
  19. International journal of molecular sciences · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mitchell CheungCancer Biology Program and Genomics Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Yuwaraj KadariyaCancer Biology Program and Genomics Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Jacqueline TalarchekCancer Biology Program and Genomics Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Jianming PeiCancer Biology Program and Genomics Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Jill A OharSection of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1054, USA.
Omar R KayalehUniversity of Florida Health Cancer Center at Orlando Health, Orlando, FL 32806, USA.
Joseph R TestaCancer Biology Program and Genomics Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Electronic address: joseph.testa@fccc.edu.
Fox Chase Cancer Center · USOrlando Health · USWake Forest University · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
Environmental Science Project 3 - Social Determinants of Risk and Attitudes AboutP42ES023720 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI BLAIR, IAN ALEXANDER · 2014 to 2018
$11.3M
Pathogenesis of Malignant Mesothelioma by the Human Polycomb Complex BAP1-ASXLR01CA175691 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI RAUSCHER III, FRANK JOSEPH, TESTA, JOSEPH R. · 2014 to 2018
$2.7M
NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA06927NCI NIH HHS R01 CA175691NIEHS NIH HHS P42 ES023720
6 · The paper itself

Abstract

We report a high-risk cancer family with multiple mesotheliomas, cutaneous melanomas, basal cell carcinomas, and meningiomas segregating with a germline nonsense mutation in BAP1 (c.1938T>A; p.Y646X). Notably, most (four of five) mesotheliomas were peritoneal rather than the usually more common pleural form of the disease, and all five mesothelioma patients also developed second or third primary cancers, including two with meningiomas. Another family member developed both cutaneous melanoma and breast cancer. Two family members had basal cell carcinomas, and six others had melanocytic tumors, including four cutaneous melanomas, one uveal melanoma, and one benign melanocytic tumor. The family resides in a subtropical area, and several members had suspected exposure to asbestos either occupationally or in the home. We hypothesize that the concurrence of a genetic predisposing factor and environmental exposure to asbestos and UV irradiation contributed to the high incidence of multiple cancers seen in this family, specifically mesothelioma and various uveal/skin tumors, respectively.

Indexed as

AsbestosCutaneous Malignant MelanomaDisease SusceptibilityGene-Environment InteractionGerm-Line MutationHumansIncidenceMelanomaNeoplasmsSkin NeoplasmsTumor Suppressor ProteinsUbiquitin ThiolesteraseAsbestosBAP1 protein, humanTumor Suppressor ProteinsUbiquitin ThiolesteraseAsbestosBAP1Cancer predispositionFamilial cancerMalignant mesothelioma

Identifiers

PMID26409435
PMCPMC4634709
OpenAlexW2117596181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.